Herbai G, Blom B, Boström H
Acta Med Scand. 1977;201(3):203-6. doi: 10.1111/j.0954-6820.1977.tb15682.x.
Cyclofenil is a new diphenyl ethylene derivative related to stilboestrol without oestrogenicity but with marked effects on connective tissue metabolism. The drug has been tested, in a daily dose of 200mg X3, in six patients with progressive systemic sclerosis (PSS) to analyze the expected beneficial effects on the PSS symptoms. The typical skin hardness, joint and muscle rigidity, and reduced breathing capacity were improved to varying dgrees. The only side-effect was a slight transient liver enzyme elevation in 1 out of 6 patients. A slight increase was found in urinary calcium and hydroxyproline excretion. In several cases serum calcium, cholesterol, triglyceride and in some cases the serum uric acid levels were decreased. The ANF titres diminished to varying degrees in 4 out of 6 patients. These results indicate that further detailed clinical and laboratory studies on the therapeutic potential of cyclofenil in PSS and other diseases affecting connective tissue seen to be justified.
环苯吩嗪是一种新的二苯乙烯衍生物，与己烯雌酚有关，无雌激素活性，但对结缔组织代谢有显著影响。该药物已以每日剂量200mg×3对6例进行性系统性硬化症（PSS）患者进行了测试，以分析其对PSS症状预期的有益作用。典型的皮肤硬度、关节和肌肉僵硬以及呼吸能力下降均有不同程度的改善。唯一的副作用是6例患者中有1例出现轻微的一过性肝酶升高。尿钙和羟脯氨酸排泄略有增加。在几例患者中，血清钙、胆固醇、甘油三酯以及部分患者的血清尿酸水平有所下降。6例患者中有4例抗核因子滴度有不同程度降低。这些结果表明，对环苯吩嗪在PSS及其他影响结缔组织疾病中的治疗潜力进行进一步详细的临床和实验室研究似乎是合理的。
